数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Andrew L. Ross Chairman of the Board 72 未披露 未持股 2021-06-16
Christopher Ianelli Chief Executive Officer, President, and Director 54 25.00万美元 未持股 2021-06-16
Jill Mullan Chief Operating Officer, Secretary, Treasurer, and Director 56 23.00万美元 未持股 2021-06-16
George Scholl Director 61 未披露 未持股 2021-06-16
Steven Gullans Director 67 未披露 未持股 2021-06-16
John L. Brooks III Director 69 未披露 未持股 2021-06-16
Margaret H. Lawrence Director 45 未披露 未持股 2021-06-16

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Christopher Ianelli Chief Executive Officer, President, and Director 54 25.00万美元 未持股 2021-06-16
Tracy Curley Chief Financial Officer 59 10.56万美元 未持股 2021-06-16
Jill Mullan Chief Operating Officer, Secretary, Treasurer, and Director 56 23.00万美元 未持股 2021-06-16
Benjamin Bielak Chief Information Officer 51 22.00万美元 未持股 2021-06-16

董事简历

中英对照 |  中文 |  英文
Andrew L. Ross

Andrew L. Ross自2012年起担任iSpecimen Inc.的董事。他已经做了将近50年的企业家和投资者。他通过控股实体开发、融资、拥有和管理多个房地产资产,包括公寓、酒店、高尔夫球场、公寓项目、若干办公和零售商业地产。自2010年以来,罗斯一直专注于天使和早期投资,主要投资于生物技术和协同消费业务。他曾以种子、天使或a轮投资人的身份投资并为多家早期企业提供咨询。Ross先生于2013年至2020年2月担任Q-State Holdings,Inc.董事会董事。


Andrew L. Ross has been serving as our director since 2012. He has been an entrepreneur and investor for almost 50 years. He developed, financed, owned and managed through controlled entities multiple real estate assets, including apartment units, hotels, a golf course, a condominium project, several office and retail commercial properties. Since 2010 Mr. Ross has focused on angel and early-stage investments primarily in biotech and collaborative consumption businesses. He has invested in and advised multiple early-stage enterprises as a seed, angel or A-round investor. Mr. Ross served as a director on the board of Q-State Holdings, Inc., from 2013 to February 2020.
Andrew L. Ross自2012年起担任iSpecimen Inc.的董事。他已经做了将近50年的企业家和投资者。他通过控股实体开发、融资、拥有和管理多个房地产资产,包括公寓、酒店、高尔夫球场、公寓项目、若干办公和零售商业地产。自2010年以来,罗斯一直专注于天使和早期投资,主要投资于生物技术和协同消费业务。他曾以种子、天使或a轮投资人的身份投资并为多家早期企业提供咨询。Ross先生于2013年至2020年2月担任Q-State Holdings,Inc.董事会董事。
Andrew L. Ross has been serving as our director since 2012. He has been an entrepreneur and investor for almost 50 years. He developed, financed, owned and managed through controlled entities multiple real estate assets, including apartment units, hotels, a golf course, a condominium project, several office and retail commercial properties. Since 2010 Mr. Ross has focused on angel and early-stage investments primarily in biotech and collaborative consumption businesses. He has invested in and advised multiple early-stage enterprises as a seed, angel or A-round investor. Mr. Ross served as a director on the board of Q-State Holdings, Inc., from 2013 to February 2020.
Christopher Ianelli

Christopher Ianelli先生自2009年7月创立iSpecimen以来一直担任iSpecimen Inc.的首席执行官、总裁和董事。Ianelli先生是Abkine Pharmaceuticals,Inc.的创始人并担任首席执行官。2009年11月至2011年12月,一家处于发展阶段的生物制药公司,开创了基于白细胞介素16信号和化学吸引中断的炎症和自身免疫性疾病治疗创新方法。Ianelli博士曾担任Leerink Partners(前身为Leerink Swann)的总经理,是一家领先的医疗保健和生命科学投资银行,2003年8月至2008年3月期间,他负责管理服务的扩展和交付,并指导战略为公司开发新的医疗保健数据和信息资产。在此之前,Ianelli博士是波士顿医疗和科学顾问公司的联合创始人和常务董事,最终由Leeink收购的一家医疗投资研究公司,从2000到2003。Ianelli博士获得了洛厄尔大学的生物科学学士学位和博士学位。在免疫学和他的医学博士从塔夫斯大学。他在布里格姆女子医院和哈佛医学院完成了住院医师培训,其中包括一年的首席住院医师。


Christopher Ianelli has been serving as our Chief Executive Officer, President, and director since founding iSpecimen in July 2009. Mr. Ianelli is the founder of and served as Chief Executive Officer of Abkine Pharmaceuticals, Inc., a development stage biopharmaceutical company pioneering innovative approaches to treatment of inflammatory and autoimmune diseases based on disruption of interleukin 16 signaling and chemoattraction from November 2009 to December 2011. Dr. Ianelli served as Managing Director at Leerink Partners formerly Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm from August 2003 to March 2008. Prior to that, Dr. Ianelli was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink, from 2000 to 2003. Dr. Ianelli received his Bachelor of Science degree in Biological Sciences from University of Lowell and both his Ph.D. in Immunology and his M.D. from Tufts University. He completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women's Hospital and Harvard Medical School.
Christopher Ianelli先生自2009年7月创立iSpecimen以来一直担任iSpecimen Inc.的首席执行官、总裁和董事。Ianelli先生是Abkine Pharmaceuticals,Inc.的创始人并担任首席执行官。2009年11月至2011年12月,一家处于发展阶段的生物制药公司,开创了基于白细胞介素16信号和化学吸引中断的炎症和自身免疫性疾病治疗创新方法。Ianelli博士曾担任Leerink Partners(前身为Leerink Swann)的总经理,是一家领先的医疗保健和生命科学投资银行,2003年8月至2008年3月期间,他负责管理服务的扩展和交付,并指导战略为公司开发新的医疗保健数据和信息资产。在此之前,Ianelli博士是波士顿医疗和科学顾问公司的联合创始人和常务董事,最终由Leeink收购的一家医疗投资研究公司,从2000到2003。Ianelli博士获得了洛厄尔大学的生物科学学士学位和博士学位。在免疫学和他的医学博士从塔夫斯大学。他在布里格姆女子医院和哈佛医学院完成了住院医师培训,其中包括一年的首席住院医师。
Christopher Ianelli has been serving as our Chief Executive Officer, President, and director since founding iSpecimen in July 2009. Mr. Ianelli is the founder of and served as Chief Executive Officer of Abkine Pharmaceuticals, Inc., a development stage biopharmaceutical company pioneering innovative approaches to treatment of inflammatory and autoimmune diseases based on disruption of interleukin 16 signaling and chemoattraction from November 2009 to December 2011. Dr. Ianelli served as Managing Director at Leerink Partners formerly Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm from August 2003 to March 2008. Prior to that, Dr. Ianelli was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink, from 2000 to 2003. Dr. Ianelli received his Bachelor of Science degree in Biological Sciences from University of Lowell and both his Ph.D. in Immunology and his M.D. from Tufts University. He completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women's Hospital and Harvard Medical School.
Jill Mullan

Jill Mullan自2013年8月起担任iSpecimen Inc.的首席运营官,自2012年11月起担任秘书,自2017年2月起担任财务主管,自2014年10月起担任董事。她于2010年加入iSpecimen Inc.公司,担任营销副总裁。2008年至2010年,她在计算机软件公司AppNeta担任营销/战略顾问。2003年至2008年,她在多家技术型公司(包括EMC和Planon software)担任营销和业务战略顾问。从2000年到2003年,Mullan女士是Storigen Systems的创始团队和营销总监,Storigen Systems是一家分布式存储网络供应商,她在Storigen Systems建立并管理公司的产品营销、通信和公共关系组织;开发了公司的品牌标识,并推出了几款成功的产品。1996年至2000年,她还受雇于Avid Technology,最近一次担任产品营销和管理总监,负责Avid的编辑产品线。在此之前,穆兰曾在IBM、MIPS计算机系统公司和惠普公司从事产品管理和工程工作。Mullan女士曾担任Westford教育基金会的财务主管和董事会成员。她毕业于康奈尔大学,获电气工程学士学位,获斯坦福大学工商管理硕士学位,专注于创业和市场营销。


Jill Mullan has been serving our Chief Operating Officer since August 2013 Secretary since November 2012 Treasurer since February 2017 and director since October 2014. She joined the Company in 2010 as the Vice President of Marketing. She was a marketing/strategy consultant at AppNeta, a computer software company, from 2008 to 2010. From 2003 to 2008 she was a marketing and business strategy consultant to various technology-based companies including EMC and Planon Software. From 2000 to 2003 Ms. Mullan was on the founding team and Director of Marketing at Storigen Systems, a provider of distributed storage networks, where she built and ran the company's product marketing, communications, and public relations organization; developed the company's brand identity and launched several successful products. She was also employed at Avid Technology from 1996 to 2000 most recently as a Director of Product Marketing and Management with product responsibility for Avid's editing product line. Prior to that, Ms. Mullan worked in product management and engineering roles at IBM, MIPS Computer Systems, and Hewlett Packard. Ms. Mullan formerly served as treasurer and board member of the Westford Education Foundation. She graduated with distinction from Cornell University with a Bachelor of Science in electrical engineering and received a Master of Business Administration from Stanford University with a focus on entrepreneurship and marketing.
Jill Mullan自2013年8月起担任iSpecimen Inc.的首席运营官,自2012年11月起担任秘书,自2017年2月起担任财务主管,自2014年10月起担任董事。她于2010年加入iSpecimen Inc.公司,担任营销副总裁。2008年至2010年,她在计算机软件公司AppNeta担任营销/战略顾问。2003年至2008年,她在多家技术型公司(包括EMC和Planon software)担任营销和业务战略顾问。从2000年到2003年,Mullan女士是Storigen Systems的创始团队和营销总监,Storigen Systems是一家分布式存储网络供应商,她在Storigen Systems建立并管理公司的产品营销、通信和公共关系组织;开发了公司的品牌标识,并推出了几款成功的产品。1996年至2000年,她还受雇于Avid Technology,最近一次担任产品营销和管理总监,负责Avid的编辑产品线。在此之前,穆兰曾在IBM、MIPS计算机系统公司和惠普公司从事产品管理和工程工作。Mullan女士曾担任Westford教育基金会的财务主管和董事会成员。她毕业于康奈尔大学,获电气工程学士学位,获斯坦福大学工商管理硕士学位,专注于创业和市场营销。
Jill Mullan has been serving our Chief Operating Officer since August 2013 Secretary since November 2012 Treasurer since February 2017 and director since October 2014. She joined the Company in 2010 as the Vice President of Marketing. She was a marketing/strategy consultant at AppNeta, a computer software company, from 2008 to 2010. From 2003 to 2008 she was a marketing and business strategy consultant to various technology-based companies including EMC and Planon Software. From 2000 to 2003 Ms. Mullan was on the founding team and Director of Marketing at Storigen Systems, a provider of distributed storage networks, where she built and ran the company's product marketing, communications, and public relations organization; developed the company's brand identity and launched several successful products. She was also employed at Avid Technology from 1996 to 2000 most recently as a Director of Product Marketing and Management with product responsibility for Avid's editing product line. Prior to that, Ms. Mullan worked in product management and engineering roles at IBM, MIPS Computer Systems, and Hewlett Packard. Ms. Mullan formerly served as treasurer and board member of the Westford Education Foundation. She graduated with distinction from Cornell University with a Bachelor of Science in electrical engineering and received a Master of Business Administration from Stanford University with a focus on entrepreneurship and marketing.
George Scholl

George Scholl自2014年起担任iSpecimen Inc.的董事。他在大部分职业生涯中都是一名企业家,主要专注于购买和处理各种行业和资产类型的不良资产。他开发并投资了金融、房地产、服务和科技公司。斯科尔目前担任OneBlood的总裁兼首席执行官,OneBlood成立于2012年,是他担任佛罗里达社区血液中心(美国东南部三大血液中心之一)主席兼首席执行官时组织的一次合并。Scholl先生目前任职于安全输血服务公司董事会,担任总部位于荷兰阿姆斯特丹的Sanquin Plasma Products B.V。审计委员会主席,同时担任监管委员会主席和总部位于以色列特拉维夫的OrSense Ltd.主席。他还曾在HemaCare公司董事会任职四年,直到2020年1月被查尔斯河实验室收购。Scholl先生目前还担任佛罗里达州Sunny Isles Beach市市长,在担任市专员7年后,于2014年当选。肖勒先生毕业于佛罗里达大学,拥有计算机科学工程学位。


George Scholl has been serving as our director since 2014. He has been an entrepreneur for most of his professional life, primarily focused on purchasing and working out distressed assets across a variety of industries and asset types. He has developed and invested in financial, real estate, service and technology companies. Mr. Scholl currently serves as the President and Chief Executive Officer of OneBlood, which was formed in 2012 as a result of a merger he organized when he was Chairman and Chief Executive Officer of the Community Blood Centers of Florida, one of the three largest blood centers in the southeastern United States. Mr. Scholl currently serves on the boards of Secure Transfusion Services, Inc. where he chairs the audit committee, Sanquin Plasma Products B.V., headquartered in Amsterdam, the Netherlands, where he chairs the regulatory committee and OrSense Ltd. headquartered in Tel Aviv, Israel. He also served for four years on the board of HemaCare Corporation until it was acquired by Charles River Laboratories in January 2020. Mr. Scholl also currently serves as the Mayor of the City of Sunny Isles Beach, Florida, where he was elected in 2014 after serving as City Commissioner for 7 years. Mr. Scholl is a graduate of the University of Florida and holds an engineering degree in computer science.
George Scholl自2014年起担任iSpecimen Inc.的董事。他在大部分职业生涯中都是一名企业家,主要专注于购买和处理各种行业和资产类型的不良资产。他开发并投资了金融、房地产、服务和科技公司。斯科尔目前担任OneBlood的总裁兼首席执行官,OneBlood成立于2012年,是他担任佛罗里达社区血液中心(美国东南部三大血液中心之一)主席兼首席执行官时组织的一次合并。Scholl先生目前任职于安全输血服务公司董事会,担任总部位于荷兰阿姆斯特丹的Sanquin Plasma Products B.V。审计委员会主席,同时担任监管委员会主席和总部位于以色列特拉维夫的OrSense Ltd.主席。他还曾在HemaCare公司董事会任职四年,直到2020年1月被查尔斯河实验室收购。Scholl先生目前还担任佛罗里达州Sunny Isles Beach市市长,在担任市专员7年后,于2014年当选。肖勒先生毕业于佛罗里达大学,拥有计算机科学工程学位。
George Scholl has been serving as our director since 2014. He has been an entrepreneur for most of his professional life, primarily focused on purchasing and working out distressed assets across a variety of industries and asset types. He has developed and invested in financial, real estate, service and technology companies. Mr. Scholl currently serves as the President and Chief Executive Officer of OneBlood, which was formed in 2012 as a result of a merger he organized when he was Chairman and Chief Executive Officer of the Community Blood Centers of Florida, one of the three largest blood centers in the southeastern United States. Mr. Scholl currently serves on the boards of Secure Transfusion Services, Inc. where he chairs the audit committee, Sanquin Plasma Products B.V., headquartered in Amsterdam, the Netherlands, where he chairs the regulatory committee and OrSense Ltd. headquartered in Tel Aviv, Israel. He also served for four years on the board of HemaCare Corporation until it was acquired by Charles River Laboratories in January 2020. Mr. Scholl also currently serves as the Mayor of the City of Sunny Isles Beach, Florida, where he was elected in 2014 after serving as City Commissioner for 7 years. Mr. Scholl is a graduate of the University of Florida and holds an engineering degree in computer science.
Steven Gullans

Steven Gullans自2020年10月起担任iSpecimen Inc.的董事。从2018年5月到2019年12月,他担任Gemphire Therapeutics的总裁兼首席执行官和董事,直到被NeuroBo Pharmaceuticals收购。在Gemphire期间,他监督与临床试验、制造、财务、业务发展、研发和知识产权相关的活动。在加入Gemphire之前,他曾于2008年3月至2018年5月担任总部位于波士顿的风险投资公司Excel Venture Management,LLC“Excel”的董事总经理。在Excel,他专注于投资生命科学技术公司,特别关注可能影响多个行业的颠覆性平台。在加入Excel之前,Gullans先生与人共同创建了RxGen,Inc.,这是一家制药服务公司,2004年2月至2008年2月期间,他还担任首席执行官和董事。在此之前,他是美国基因组公司(US Genomics,Inc.)的首席科学官,美国基因组公司开发用于病原体检测的DNA分析技术,2002年11月至2004年1月,Gullans先生担任药物开发公司Orionis Biosciences的董事。他曾是Activate Networks,Inc.的董事会成员,Activate Networks,Inc.被Decision Resource Group收购,nanoMR Inc.被DNA Electronics Ltd收购,Tetraphase Pharmaceuticals,Inc.于2013年上市,Molecular Templates,古兰斯先生曾在哈佛医学院和布里格姆女子医院担任教员近20年。古兰斯先生拥有联合学院的学士学位和博士学位。来自杜克大学。


Steven Gullans has been serving as our director since October 2020. From May 2018 to December 2019 he served as President and Chief Executive Officer and Director of Gemphire Therapeutics, until it was acquired by NeuroBo Pharmaceuticals. While at Gemphire, he oversaw activities related to clinical trials,manufacturing, finances, business development, R&D and intellectual property. Prior to Gemphire, he was Managing Director at Excel Venture Management, LLC "Excel", a Boston-based venture capital firm which he co-founded, from March 2008 to May 2018. At Excel, he focused on investing in life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Mr. Gullans co-founded RxGen, Inc., a pharmaceutical services company, where he also served as Chief Executive Officer and a director from February 2004 to February 2008. Prior to that, he was the Chief Scientific Officer of US Genomics, Inc., a company that develops technology to analyze DNA for pathogen detection, from November 2002 to January 2004. Mr. Gullans serves as a director at Orionis Biosciences, a drug development company. He was previously a board member of Activate Networks, Inc. which was acquired by Decision Resource Group, nanoMR Inc., which was acquired by DNA Electronics Ltd, Tetraphase Pharmaceuticals, Inc. which went public in 2013 and Molecular Templates, Inc. which was merged into a public entity in 2017. Mr. Gullans was a faculty member at Harvard Medical School and Brigham and Women's Hospital for almost 20 years. Mr. Gullans holds a B.S. from Union College and a Ph.D. from Duke University.
Steven Gullans自2020年10月起担任iSpecimen Inc.的董事。从2018年5月到2019年12月,他担任Gemphire Therapeutics的总裁兼首席执行官和董事,直到被NeuroBo Pharmaceuticals收购。在Gemphire期间,他监督与临床试验、制造、财务、业务发展、研发和知识产权相关的活动。在加入Gemphire之前,他曾于2008年3月至2018年5月担任总部位于波士顿的风险投资公司Excel Venture Management,LLC“Excel”的董事总经理。在Excel,他专注于投资生命科学技术公司,特别关注可能影响多个行业的颠覆性平台。在加入Excel之前,Gullans先生与人共同创建了RxGen,Inc.,这是一家制药服务公司,2004年2月至2008年2月期间,他还担任首席执行官和董事。在此之前,他是美国基因组公司(US Genomics,Inc.)的首席科学官,美国基因组公司开发用于病原体检测的DNA分析技术,2002年11月至2004年1月,Gullans先生担任药物开发公司Orionis Biosciences的董事。他曾是Activate Networks,Inc.的董事会成员,Activate Networks,Inc.被Decision Resource Group收购,nanoMR Inc.被DNA Electronics Ltd收购,Tetraphase Pharmaceuticals,Inc.于2013年上市,Molecular Templates,古兰斯先生曾在哈佛医学院和布里格姆女子医院担任教员近20年。古兰斯先生拥有联合学院的学士学位和博士学位。来自杜克大学。
Steven Gullans has been serving as our director since October 2020. From May 2018 to December 2019 he served as President and Chief Executive Officer and Director of Gemphire Therapeutics, until it was acquired by NeuroBo Pharmaceuticals. While at Gemphire, he oversaw activities related to clinical trials,manufacturing, finances, business development, R&D and intellectual property. Prior to Gemphire, he was Managing Director at Excel Venture Management, LLC "Excel", a Boston-based venture capital firm which he co-founded, from March 2008 to May 2018. At Excel, he focused on investing in life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Mr. Gullans co-founded RxGen, Inc., a pharmaceutical services company, where he also served as Chief Executive Officer and a director from February 2004 to February 2008. Prior to that, he was the Chief Scientific Officer of US Genomics, Inc., a company that develops technology to analyze DNA for pathogen detection, from November 2002 to January 2004. Mr. Gullans serves as a director at Orionis Biosciences, a drug development company. He was previously a board member of Activate Networks, Inc. which was acquired by Decision Resource Group, nanoMR Inc., which was acquired by DNA Electronics Ltd, Tetraphase Pharmaceuticals, Inc. which went public in 2013 and Molecular Templates, Inc. which was merged into a public entity in 2017. Mr. Gullans was a faculty member at Harvard Medical School and Brigham and Women's Hospital for almost 20 years. Mr. Gullans holds a B.S. from Union College and a Ph.D. from Duke University.
John L. Brooks III

John L. Brooks III担任iSpecimen Inc.董事。他还自2008年11月起担任Hemoshear Therapeutics董事,自2009年3月起担任Noxilizer董事,自2016年6月起担任Hygieia董事,自2020年3月起担任Atentiv董事。自2009年1月起,他还担任Thermalin,Inc.董事长。2012年1月,Brooks先生成立了Ammonett Pharma,并自那时起继续担任其董事会成员。自2007年2月起,他还担任Healthcare Capital LLC的常务董事。此前,布鲁克斯先生在2018年3月至2019年12月期间担任NeuroBo Pharmaceuticals,Inc.的首席执行官、总裁和董事,并担任Cellnovo的董事长,布鲁克斯先生还参与了多个非营利组织。他自2019年1月起担任全球临床教育和研究创新网络的首席执行官和总裁,自2020年3月起担任T1D交换主任,自2015年1月以来艾达新英格兰一章自2015年1月以来的人口健康联盟和大学。马萨诸塞州阿默斯特基金会自2012年1月起,他自2011年1月起还担任学院糖尿病网络主席,自2012年3月起还在萨福克大学董事会任职。布鲁克斯先生在麻州大学阿默斯特分校获得了BBA和MBA学位。


John L. Brooks III has been serving as our director since the date hereof. He currently also serves as a director of Hemoshear Therapeutics since November 2008 Noxilizer since March 2009 Hygieia since June 2016 and Atentiv since March 2020. He also serves as the chairman of Thermalin, Inc. since January 2009. In January 2012 Mr. Brooks founded Ammonett Pharma and continues to serve on its board of directors since then. He has also served as the managing director of Healthcare Capital LLC since February 2007. Previously, Mr. Brooks served as the Chief Executive Officer, President and a director of NeuroBo Pharmaceuticals, Inc. from March 2018 to December 2019 and as the chairman of Cellnovo, Ltd. from 2012 to December 2019. Mr. Brooks is also involved with several non-profit organizations. He currently serves as the Chief Executive Officer and President of Worldwide Network for Innovation in Clinical Education and Research WNICER since January 2019 and also serves as a director of T1D Exchange since March 2020 the ADA New England Chapter since January 2015 Population Health Alliance since January 2014 and the University of Massachusetts Amherst Foundation since January 2012. He also chairs the College Diabetes Network since January 2011 and is also on the board of trustees of Suffolk University since March 2012. Mr. Brooks received his BBA and MSBA in Accounting from the University of Massachusetts Amherst.
John L. Brooks III担任iSpecimen Inc.董事。他还自2008年11月起担任Hemoshear Therapeutics董事,自2009年3月起担任Noxilizer董事,自2016年6月起担任Hygieia董事,自2020年3月起担任Atentiv董事。自2009年1月起,他还担任Thermalin,Inc.董事长。2012年1月,Brooks先生成立了Ammonett Pharma,并自那时起继续担任其董事会成员。自2007年2月起,他还担任Healthcare Capital LLC的常务董事。此前,布鲁克斯先生在2018年3月至2019年12月期间担任NeuroBo Pharmaceuticals,Inc.的首席执行官、总裁和董事,并担任Cellnovo的董事长,布鲁克斯先生还参与了多个非营利组织。他自2019年1月起担任全球临床教育和研究创新网络的首席执行官和总裁,自2020年3月起担任T1D交换主任,自2015年1月以来艾达新英格兰一章自2015年1月以来的人口健康联盟和大学。马萨诸塞州阿默斯特基金会自2012年1月起,他自2011年1月起还担任学院糖尿病网络主席,自2012年3月起还在萨福克大学董事会任职。布鲁克斯先生在麻州大学阿默斯特分校获得了BBA和MBA学位。
John L. Brooks III has been serving as our director since the date hereof. He currently also serves as a director of Hemoshear Therapeutics since November 2008 Noxilizer since March 2009 Hygieia since June 2016 and Atentiv since March 2020. He also serves as the chairman of Thermalin, Inc. since January 2009. In January 2012 Mr. Brooks founded Ammonett Pharma and continues to serve on its board of directors since then. He has also served as the managing director of Healthcare Capital LLC since February 2007. Previously, Mr. Brooks served as the Chief Executive Officer, President and a director of NeuroBo Pharmaceuticals, Inc. from March 2018 to December 2019 and as the chairman of Cellnovo, Ltd. from 2012 to December 2019. Mr. Brooks is also involved with several non-profit organizations. He currently serves as the Chief Executive Officer and President of Worldwide Network for Innovation in Clinical Education and Research WNICER since January 2019 and also serves as a director of T1D Exchange since March 2020 the ADA New England Chapter since January 2015 Population Health Alliance since January 2014 and the University of Massachusetts Amherst Foundation since January 2012. He also chairs the College Diabetes Network since January 2011 and is also on the board of trustees of Suffolk University since March 2012. Mr. Brooks received his BBA and MSBA in Accounting from the University of Massachusetts Amherst.
Margaret H. Lawrence

Margaret H. Lawrence担任iSpecimen Inc.董事。劳伦斯女士是一位经验丰富的创业型高管,在财务方面有十多年的经验,也是软件行业的风险投资家。在过去的十年里,她一直在高增长科技公司担任综合管理领导职务。她目前担任Wayfair Professional的总经理,负责损益,领导一支庞大的团队,并从2016年11月起负责业务战略、客户体验、销售效率、品牌开发、技术和销售策略等全方位的专业知识。在加入Wayfair之前,Lawrence女士于2016年担任基于SaaS的费用报销公司Motus的首席服务官。她曾于2011年至2015年在谷歌工作,最近担任谷歌美洲中小型企业组织的办公室主任,负责美洲地区的战略和运营。在谷歌之前,劳伦斯是总部位于波士顿的早期风险投资公司Pilot House Ventures的合伙人。她领导了许多早期科技公司的投资过程,并在这些公司担任董事会成员。在过去的15年里,劳伦斯女士担任了多个董事会职位,这是她参与社区活动以及从事风险投资事业的一部分。2011年至2017年,她在马萨诸塞州计划生育联盟董事会任职,并担任财务委员会和投资委员会主席数年,其中包括首席财务官和首席执行官的过渡。她目前仍然作为财务委员会的成员参与马萨诸塞州计划生育联盟。此外,Lawrence女士于2011年至2014年在云杉街董事会任职,并担任云杉街财务委员会成员。Lawrence女士获得威廉姆斯学院经济学学士学位和哈佛商学院工商管理硕士学位。


Margaret H. Lawrence has been serving as our director since the date hereof. Ms. Lawrence is an experienced, entrepreneurial executive with over a decade's experience in finance roles and as a venture capital investor in the software industry. She has spent the last decade in general management leadership roles at high growth technology companies. She currently serves as a General Manager Wayfair Professional in which role she owns the P&L, leads a large team and the full range of disciplines, including business strategy, customer experience, sales effectiveness, brand development, technology, and merchandising strategy since November 2016. Prior to joining Wayfair, Ms. Lawrence was Chief Services Officer at Motus, a SaaS-based expense reimbursement company, in 2016. She previously worked at Google from 2011 to 2015 most recently as the Chief of Staff for Google's Small and Medium Business organization for the Americas, running strategy and operations for the region. Prior to Google, Ms. Lawrence was a Partner at Pilot House Ventures, a Boston-based early stage venture capital firm. She led the investment process for and held board seats at a number of early stage technology companies. Over the last 15 years, Ms. Lawrence has held several board positions as part of her community engagement as well as her venture capital career. She was on the Planned Parenthood League of Massachusetts board from 2011 to 2017 and served as the Chair of both the Finance Committee and Investment Committee for several years which included a CFO and CEO transition. She currently remains involved in the Planned Parenthood League of Massachusetts as a member of the Finance Committee. Additionally, Ms. Lawrence served on the Spruce Street Nursery School Board and as a member of its Finance Committee from 2011 to 2014. Ms. Lawrence received her BA in economics from Williams College and an MBA from Harvard Business School.
Margaret H. Lawrence担任iSpecimen Inc.董事。劳伦斯女士是一位经验丰富的创业型高管,在财务方面有十多年的经验,也是软件行业的风险投资家。在过去的十年里,她一直在高增长科技公司担任综合管理领导职务。她目前担任Wayfair Professional的总经理,负责损益,领导一支庞大的团队,并从2016年11月起负责业务战略、客户体验、销售效率、品牌开发、技术和销售策略等全方位的专业知识。在加入Wayfair之前,Lawrence女士于2016年担任基于SaaS的费用报销公司Motus的首席服务官。她曾于2011年至2015年在谷歌工作,最近担任谷歌美洲中小型企业组织的办公室主任,负责美洲地区的战略和运营。在谷歌之前,劳伦斯是总部位于波士顿的早期风险投资公司Pilot House Ventures的合伙人。她领导了许多早期科技公司的投资过程,并在这些公司担任董事会成员。在过去的15年里,劳伦斯女士担任了多个董事会职位,这是她参与社区活动以及从事风险投资事业的一部分。2011年至2017年,她在马萨诸塞州计划生育联盟董事会任职,并担任财务委员会和投资委员会主席数年,其中包括首席财务官和首席执行官的过渡。她目前仍然作为财务委员会的成员参与马萨诸塞州计划生育联盟。此外,Lawrence女士于2011年至2014年在云杉街董事会任职,并担任云杉街财务委员会成员。Lawrence女士获得威廉姆斯学院经济学学士学位和哈佛商学院工商管理硕士学位。
Margaret H. Lawrence has been serving as our director since the date hereof. Ms. Lawrence is an experienced, entrepreneurial executive with over a decade's experience in finance roles and as a venture capital investor in the software industry. She has spent the last decade in general management leadership roles at high growth technology companies. She currently serves as a General Manager Wayfair Professional in which role she owns the P&L, leads a large team and the full range of disciplines, including business strategy, customer experience, sales effectiveness, brand development, technology, and merchandising strategy since November 2016. Prior to joining Wayfair, Ms. Lawrence was Chief Services Officer at Motus, a SaaS-based expense reimbursement company, in 2016. She previously worked at Google from 2011 to 2015 most recently as the Chief of Staff for Google's Small and Medium Business organization for the Americas, running strategy and operations for the region. Prior to Google, Ms. Lawrence was a Partner at Pilot House Ventures, a Boston-based early stage venture capital firm. She led the investment process for and held board seats at a number of early stage technology companies. Over the last 15 years, Ms. Lawrence has held several board positions as part of her community engagement as well as her venture capital career. She was on the Planned Parenthood League of Massachusetts board from 2011 to 2017 and served as the Chair of both the Finance Committee and Investment Committee for several years which included a CFO and CEO transition. She currently remains involved in the Planned Parenthood League of Massachusetts as a member of the Finance Committee. Additionally, Ms. Lawrence served on the Spruce Street Nursery School Board and as a member of its Finance Committee from 2011 to 2014. Ms. Lawrence received her BA in economics from Williams College and an MBA from Harvard Business School.

高管简历

中英对照 |  中文 |  英文
Christopher Ianelli

Christopher Ianelli先生自2009年7月创立iSpecimen以来一直担任iSpecimen Inc.的首席执行官、总裁和董事。Ianelli先生是Abkine Pharmaceuticals,Inc.的创始人并担任首席执行官。2009年11月至2011年12月,一家处于发展阶段的生物制药公司,开创了基于白细胞介素16信号和化学吸引中断的炎症和自身免疫性疾病治疗创新方法。Ianelli博士曾担任Leerink Partners(前身为Leerink Swann)的总经理,是一家领先的医疗保健和生命科学投资银行,2003年8月至2008年3月期间,他负责管理服务的扩展和交付,并指导战略为公司开发新的医疗保健数据和信息资产。在此之前,Ianelli博士是波士顿医疗和科学顾问公司的联合创始人和常务董事,最终由Leeink收购的一家医疗投资研究公司,从2000到2003。Ianelli博士获得了洛厄尔大学的生物科学学士学位和博士学位。在免疫学和他的医学博士从塔夫斯大学。他在布里格姆女子医院和哈佛医学院完成了住院医师培训,其中包括一年的首席住院医师。


Christopher Ianelli has been serving as our Chief Executive Officer, President, and director since founding iSpecimen in July 2009. Mr. Ianelli is the founder of and served as Chief Executive Officer of Abkine Pharmaceuticals, Inc., a development stage biopharmaceutical company pioneering innovative approaches to treatment of inflammatory and autoimmune diseases based on disruption of interleukin 16 signaling and chemoattraction from November 2009 to December 2011. Dr. Ianelli served as Managing Director at Leerink Partners formerly Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm from August 2003 to March 2008. Prior to that, Dr. Ianelli was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink, from 2000 to 2003. Dr. Ianelli received his Bachelor of Science degree in Biological Sciences from University of Lowell and both his Ph.D. in Immunology and his M.D. from Tufts University. He completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women's Hospital and Harvard Medical School.
Christopher Ianelli先生自2009年7月创立iSpecimen以来一直担任iSpecimen Inc.的首席执行官、总裁和董事。Ianelli先生是Abkine Pharmaceuticals,Inc.的创始人并担任首席执行官。2009年11月至2011年12月,一家处于发展阶段的生物制药公司,开创了基于白细胞介素16信号和化学吸引中断的炎症和自身免疫性疾病治疗创新方法。Ianelli博士曾担任Leerink Partners(前身为Leerink Swann)的总经理,是一家领先的医疗保健和生命科学投资银行,2003年8月至2008年3月期间,他负责管理服务的扩展和交付,并指导战略为公司开发新的医疗保健数据和信息资产。在此之前,Ianelli博士是波士顿医疗和科学顾问公司的联合创始人和常务董事,最终由Leeink收购的一家医疗投资研究公司,从2000到2003。Ianelli博士获得了洛厄尔大学的生物科学学士学位和博士学位。在免疫学和他的医学博士从塔夫斯大学。他在布里格姆女子医院和哈佛医学院完成了住院医师培训,其中包括一年的首席住院医师。
Christopher Ianelli has been serving as our Chief Executive Officer, President, and director since founding iSpecimen in July 2009. Mr. Ianelli is the founder of and served as Chief Executive Officer of Abkine Pharmaceuticals, Inc., a development stage biopharmaceutical company pioneering innovative approaches to treatment of inflammatory and autoimmune diseases based on disruption of interleukin 16 signaling and chemoattraction from November 2009 to December 2011. Dr. Ianelli served as Managing Director at Leerink Partners formerly Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm from August 2003 to March 2008. Prior to that, Dr. Ianelli was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink, from 2000 to 2003. Dr. Ianelli received his Bachelor of Science degree in Biological Sciences from University of Lowell and both his Ph.D. in Immunology and his M.D. from Tufts University. He completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women's Hospital and Harvard Medical School.
Tracy Curley

Tracy Curley自2020年8月起担任iSpecimen Inc.的首席财务官。2017年9月至2020年6月,她曾在CohnReznick LLP(一家全国性会计师事务所)担任合伙人。在CohnReznick LLP任职期间,Curley女士在波士顿领导了CohnReznick LLP任新兴市场商业审计实践团队的创建和发展,文学硕士办公室。她的工作重点是为科技和生命科学行业的私营和公共新兴增长型公司招聘和提供审计服务。2014年11月至2017年8月,她还担任全国性会计师事务所Marcum LLP的合伙人。科利女士为该公司领导了东北地区的高科技业务。她专注于扩大客户群,为科技、生命科学和先进制造业等高科技行业的私营和公共新兴成长型公司提供全方位的会计、税务和咨询服务。2010年3月至2014年10月,Curley女士在Moody,Famiglietti&Andronico,LLP“MFA”担任合伙人,这是一家位于马萨诸塞州大波士顿地区的前瞻性咨询公司,业务遍及全国和全球。在MFA任职期间,Curley女士领导了上市公司审计业务的创建和发展,重点是为上市新兴成长型公司招聘和提供审计服务。科利女士是北海岸技术委员会的主席和董事会成员,也是马萨诸塞州东部女童子军和绿色学校项目的董事会成员。Curley女士毕业于堪萨斯州立大学会计专业,主修工商管理专业,主修会计和理学学士。她还参加了美国军事学院。她是马萨诸塞州注册会计师。


Tracy Curley has been serving as our Chief Financial Officer since August 2020. She was a partner at CohnReznick LLP, a national accounting firm, from September 2017 to June 2020. During her time at CohnReznick, LLP, Ms. Curley led the creation and development of an emerging markets commercial audit practice team for the firm in their Boston, MA office. Her practice focused on recruiting and providing audit services to private and public emerging growth companies in the technology and life sciences industries. From November 2014 to August 2017 she also served as a partner at Marcum LLP, a national accounting firm. Ms. Curley led the northeast regional high-tech practice for the firm. She focused on expanding the client base to provide a full range of accounting, tax and advisory services for private and public emerging growth companies in high tech industries such as technology, life sciences and advanced manufacturing. From March 2010 to October 2014 Ms. Curley served as a partner at Moody, Famiglietti & Andronico, LLP "MFA", a proactive consulting firm in the greater Boston, MA area with national and global reach. During her time at MFA, Ms. Curley led the creation and development of a public company audit practice focused on recruiting and providing audit services to public emerging growth companies. Ms. Curley serves as President and a board member of the North Shore Technology Council and as a board member of the Girl Scouts of Eastern Massachusetts and Project Green Schools. Ms. Curley received her Master of Accountancy and Bachelor of Science in Business Administration with a concentration in accounting from Kansas State University. She also attended the United States Military Academy. She is a certified public accountant licensed in the Commonwealth of Massachusetts.
Tracy Curley自2020年8月起担任iSpecimen Inc.的首席财务官。2017年9月至2020年6月,她曾在CohnReznick LLP(一家全国性会计师事务所)担任合伙人。在CohnReznick LLP任职期间,Curley女士在波士顿领导了CohnReznick LLP任新兴市场商业审计实践团队的创建和发展,文学硕士办公室。她的工作重点是为科技和生命科学行业的私营和公共新兴增长型公司招聘和提供审计服务。2014年11月至2017年8月,她还担任全国性会计师事务所Marcum LLP的合伙人。科利女士为该公司领导了东北地区的高科技业务。她专注于扩大客户群,为科技、生命科学和先进制造业等高科技行业的私营和公共新兴成长型公司提供全方位的会计、税务和咨询服务。2010年3月至2014年10月,Curley女士在Moody,Famiglietti&Andronico,LLP“MFA”担任合伙人,这是一家位于马萨诸塞州大波士顿地区的前瞻性咨询公司,业务遍及全国和全球。在MFA任职期间,Curley女士领导了上市公司审计业务的创建和发展,重点是为上市新兴成长型公司招聘和提供审计服务。科利女士是北海岸技术委员会的主席和董事会成员,也是马萨诸塞州东部女童子军和绿色学校项目的董事会成员。Curley女士毕业于堪萨斯州立大学会计专业,主修工商管理专业,主修会计和理学学士。她还参加了美国军事学院。她是马萨诸塞州注册会计师。
Tracy Curley has been serving as our Chief Financial Officer since August 2020. She was a partner at CohnReznick LLP, a national accounting firm, from September 2017 to June 2020. During her time at CohnReznick, LLP, Ms. Curley led the creation and development of an emerging markets commercial audit practice team for the firm in their Boston, MA office. Her practice focused on recruiting and providing audit services to private and public emerging growth companies in the technology and life sciences industries. From November 2014 to August 2017 she also served as a partner at Marcum LLP, a national accounting firm. Ms. Curley led the northeast regional high-tech practice for the firm. She focused on expanding the client base to provide a full range of accounting, tax and advisory services for private and public emerging growth companies in high tech industries such as technology, life sciences and advanced manufacturing. From March 2010 to October 2014 Ms. Curley served as a partner at Moody, Famiglietti & Andronico, LLP "MFA", a proactive consulting firm in the greater Boston, MA area with national and global reach. During her time at MFA, Ms. Curley led the creation and development of a public company audit practice focused on recruiting and providing audit services to public emerging growth companies. Ms. Curley serves as President and a board member of the North Shore Technology Council and as a board member of the Girl Scouts of Eastern Massachusetts and Project Green Schools. Ms. Curley received her Master of Accountancy and Bachelor of Science in Business Administration with a concentration in accounting from Kansas State University. She also attended the United States Military Academy. She is a certified public accountant licensed in the Commonwealth of Massachusetts.
Jill Mullan

Jill Mullan自2013年8月起担任iSpecimen Inc.的首席运营官,自2012年11月起担任秘书,自2017年2月起担任财务主管,自2014年10月起担任董事。她于2010年加入iSpecimen Inc.公司,担任营销副总裁。2008年至2010年,她在计算机软件公司AppNeta担任营销/战略顾问。2003年至2008年,她在多家技术型公司(包括EMC和Planon software)担任营销和业务战略顾问。从2000年到2003年,Mullan女士是Storigen Systems的创始团队和营销总监,Storigen Systems是一家分布式存储网络供应商,她在Storigen Systems建立并管理公司的产品营销、通信和公共关系组织;开发了公司的品牌标识,并推出了几款成功的产品。1996年至2000年,她还受雇于Avid Technology,最近一次担任产品营销和管理总监,负责Avid的编辑产品线。在此之前,穆兰曾在IBM、MIPS计算机系统公司和惠普公司从事产品管理和工程工作。Mullan女士曾担任Westford教育基金会的财务主管和董事会成员。她毕业于康奈尔大学,获电气工程学士学位,获斯坦福大学工商管理硕士学位,专注于创业和市场营销。


Jill Mullan has been serving our Chief Operating Officer since August 2013 Secretary since November 2012 Treasurer since February 2017 and director since October 2014. She joined the Company in 2010 as the Vice President of Marketing. She was a marketing/strategy consultant at AppNeta, a computer software company, from 2008 to 2010. From 2003 to 2008 she was a marketing and business strategy consultant to various technology-based companies including EMC and Planon Software. From 2000 to 2003 Ms. Mullan was on the founding team and Director of Marketing at Storigen Systems, a provider of distributed storage networks, where she built and ran the company's product marketing, communications, and public relations organization; developed the company's brand identity and launched several successful products. She was also employed at Avid Technology from 1996 to 2000 most recently as a Director of Product Marketing and Management with product responsibility for Avid's editing product line. Prior to that, Ms. Mullan worked in product management and engineering roles at IBM, MIPS Computer Systems, and Hewlett Packard. Ms. Mullan formerly served as treasurer and board member of the Westford Education Foundation. She graduated with distinction from Cornell University with a Bachelor of Science in electrical engineering and received a Master of Business Administration from Stanford University with a focus on entrepreneurship and marketing.
Jill Mullan自2013年8月起担任iSpecimen Inc.的首席运营官,自2012年11月起担任秘书,自2017年2月起担任财务主管,自2014年10月起担任董事。她于2010年加入iSpecimen Inc.公司,担任营销副总裁。2008年至2010年,她在计算机软件公司AppNeta担任营销/战略顾问。2003年至2008年,她在多家技术型公司(包括EMC和Planon software)担任营销和业务战略顾问。从2000年到2003年,Mullan女士是Storigen Systems的创始团队和营销总监,Storigen Systems是一家分布式存储网络供应商,她在Storigen Systems建立并管理公司的产品营销、通信和公共关系组织;开发了公司的品牌标识,并推出了几款成功的产品。1996年至2000年,她还受雇于Avid Technology,最近一次担任产品营销和管理总监,负责Avid的编辑产品线。在此之前,穆兰曾在IBM、MIPS计算机系统公司和惠普公司从事产品管理和工程工作。Mullan女士曾担任Westford教育基金会的财务主管和董事会成员。她毕业于康奈尔大学,获电气工程学士学位,获斯坦福大学工商管理硕士学位,专注于创业和市场营销。
Jill Mullan has been serving our Chief Operating Officer since August 2013 Secretary since November 2012 Treasurer since February 2017 and director since October 2014. She joined the Company in 2010 as the Vice President of Marketing. She was a marketing/strategy consultant at AppNeta, a computer software company, from 2008 to 2010. From 2003 to 2008 she was a marketing and business strategy consultant to various technology-based companies including EMC and Planon Software. From 2000 to 2003 Ms. Mullan was on the founding team and Director of Marketing at Storigen Systems, a provider of distributed storage networks, where she built and ran the company's product marketing, communications, and public relations organization; developed the company's brand identity and launched several successful products. She was also employed at Avid Technology from 1996 to 2000 most recently as a Director of Product Marketing and Management with product responsibility for Avid's editing product line. Prior to that, Ms. Mullan worked in product management and engineering roles at IBM, MIPS Computer Systems, and Hewlett Packard. Ms. Mullan formerly served as treasurer and board member of the Westford Education Foundation. She graduated with distinction from Cornell University with a Bachelor of Science in electrical engineering and received a Master of Business Administration from Stanford University with a focus on entrepreneurship and marketing.
Benjamin Bielak

Benjamin Bielak自2018年6月以来,一直担任iSpecimen Inc.的首席信息官。他在GNS Healthor公司担任首席信息官,这是一家领先的休闲机器学习产品和服务公司,从2017年1月到2018年5月,并担任哈佛大学学术技术总监。2015年2月至2017年1月。在GNS和哈佛工作之前,Bielak先生是Dovetail Health的首席信息官,Dovetail Health是一家高增长的产品和服务公司,专注于通过以制药为重点的干预措施降低成本,从2006年11月至2014年4月,他曾在波士顿医学中心担任开发与整合经理,并于1997年12月至2005年7月在全球服务公司SAUVIE公司担任高级技术经理。Bielak先生持有宾利大学工商管理硕士学位。他的研究集中于变革管理,以及波士顿大学计算机科学硕士学位。他持有两项证书,一项是医疗保健信息管理高管学院(College of Healthcare Information Management Executives CHIME Certified Healthcare Chief Information Officer,CHCIO),另一项是医疗保健信息管理系统协会(Health Information Management System Society,HIMSS)认证的医疗保健信息和管理系统专业人士(CPHIMS)。


Benjamin Bielak has been serving as our Chief Information Officer since June 2018. He served as the Chief Information Officer at GNS Healthcare, a leading casual machine learning product and services company, from January 2017 to May 2018 and as Director of Academic Technology at Harvard University, from February 2015 to January 2017. Prior to his work at GNS and Harvard, Mr. Bielak was the Chief Information Officer at Dovetail Health, a high-growth product and services company focused on reducing costs through pharmacy-focused interventions, from November 2006 to April 2014. He previously held roles as Manager of Development and Integration at Boston Medical Center and Senior Manager of Technology at Sapient, a global services company, from December 1997 to July 2005. Mr. Bielak holds a Master of Business Administration degree from Bentley University, where his studies focused on change management, and a master's degree from Boston University in computer science. He maintains two certifications, the College of Healthcare Information Management Executives CHIME Certified Healthcare Chief Information Officer (CHCIO) and the Health Information Management System Society (HIMSS) Certified Professional in Healthcare Information and Management Systems (CPHIMS).
Benjamin Bielak自2018年6月以来,一直担任iSpecimen Inc.的首席信息官。他在GNS Healthor公司担任首席信息官,这是一家领先的休闲机器学习产品和服务公司,从2017年1月到2018年5月,并担任哈佛大学学术技术总监。2015年2月至2017年1月。在GNS和哈佛工作之前,Bielak先生是Dovetail Health的首席信息官,Dovetail Health是一家高增长的产品和服务公司,专注于通过以制药为重点的干预措施降低成本,从2006年11月至2014年4月,他曾在波士顿医学中心担任开发与整合经理,并于1997年12月至2005年7月在全球服务公司SAUVIE公司担任高级技术经理。Bielak先生持有宾利大学工商管理硕士学位。他的研究集中于变革管理,以及波士顿大学计算机科学硕士学位。他持有两项证书,一项是医疗保健信息管理高管学院(College of Healthcare Information Management Executives CHIME Certified Healthcare Chief Information Officer,CHCIO),另一项是医疗保健信息管理系统协会(Health Information Management System Society,HIMSS)认证的医疗保健信息和管理系统专业人士(CPHIMS)。
Benjamin Bielak has been serving as our Chief Information Officer since June 2018. He served as the Chief Information Officer at GNS Healthcare, a leading casual machine learning product and services company, from January 2017 to May 2018 and as Director of Academic Technology at Harvard University, from February 2015 to January 2017. Prior to his work at GNS and Harvard, Mr. Bielak was the Chief Information Officer at Dovetail Health, a high-growth product and services company focused on reducing costs through pharmacy-focused interventions, from November 2006 to April 2014. He previously held roles as Manager of Development and Integration at Boston Medical Center and Senior Manager of Technology at Sapient, a global services company, from December 1997 to July 2005. Mr. Bielak holds a Master of Business Administration degree from Bentley University, where his studies focused on change management, and a master's degree from Boston University in computer science. He maintains two certifications, the College of Healthcare Information Management Executives CHIME Certified Healthcare Chief Information Officer (CHCIO) and the Health Information Management System Society (HIMSS) Certified Professional in Healthcare Information and Management Systems (CPHIMS).